Analysts Offer Predictions for VERV Q2 Earnings

Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) - Analysts at Lifesci Capital issued their Q2 2025 earnings per share estimates for shares of Verve Therapeutics in a report released on Tuesday, June 17th. Lifesci Capital analyst C. Jubinville anticipates that the company will earn ($0.71) per share for the quarter. Lifesci Capital currently has a "Hold" rating and a $12.00 price target on the stock. The consensus estimate for Verve Therapeutics' current full-year earnings is ($2.49) per share. Lifesci Capital also issued estimates for Verve Therapeutics' Q3 2025 earnings at ($0.71) EPS and Q4 2025 earnings at ($0.70) EPS.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.36. Verve Therapeutics had a negative return on equity of 35.81% and a negative net margin of 303.64%. The company had revenue of $32.98 million during the quarter, compared to analysts' expectations of $7.13 million.

Other research analysts have also recently issued research reports about the company. William Blair cut Verve Therapeutics from a "strong-buy" rating to a "market perform" rating in a research note on Tuesday, June 17th. Guggenheim increased their price target on Verve Therapeutics from $18.00 to $24.00 and gave the stock a "buy" rating in a research note on Tuesday, April 15th. Canaccord Genuity Group cut Verve Therapeutics from a "strong-buy" rating to a "hold" rating and decreased their price target for the stock from $39.00 to $13.00 in a research note on Tuesday, June 17th. Royal Bank Of Canada decreased their price target on Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating for the company in a research note on Tuesday, March 4th. Finally, HC Wainwright cut Verve Therapeutics from a "buy" rating to a "neutral" rating and set a $13.50 target price for the company. in a research note on Wednesday. Six research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $14.75.

Verve Therapeutics Stock Performance

Shares of NASDAQ:VERV traded down $0.06 on Thursday, hitting $11.06. The company's stock had a trading volume of 7,719,335 shares, compared to its average volume of 2,372,272. Verve Therapeutics has a 12 month low of $2.86 and a 12 month high of $11.41. The company has a market capitalization of $985.89 million, a price-to-earnings ratio of -5.24 and a beta of 1.67. The stock's 50-day moving average is $5.49 and its two-hundred day moving average is $5.93.

Hedge Funds Weigh In On Verve Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Acadian Asset Management LLC boosted its stake in Verve Therapeutics by 126.2% in the first quarter. Acadian Asset Management LLC now owns 30,803 shares of the company's stock worth $140,000 after purchasing an additional 17,186 shares in the last quarter. Woodline Partners LP acquired a new position in Verve Therapeutics in the first quarter worth $12,648,000. Goldman Sachs Group Inc. boosted its stake in Verve Therapeutics by 90.7% in the first quarter. Goldman Sachs Group Inc. now owns 1,413,118 shares of the company's stock worth $6,458,000 after purchasing an additional 671,939 shares in the last quarter. AQR Capital Management LLC boosted its stake in Verve Therapeutics by 1,028.7% in the first quarter. AQR Capital Management LLC now owns 373,207 shares of the company's stock worth $1,706,000 after purchasing an additional 340,143 shares in the last quarter. Finally, Alpine Global Management LLC acquired a new position in Verve Therapeutics in the first quarter worth $57,000. Institutional investors and hedge funds own 97.11% of the company's stock.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.